Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
Article in Expert Review of Pharmacoeconomics & Outcomes Research (July 2024)
The most recent citing publication is shown below. View this citation on Dimensions.
Article in Expert Review of Pharmacoeconomics & Outcomes Research (July 2024)